StudyFinder
An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma (ccRCC) in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab)
Status: Recruiting
This Expanded Access Program (EAP) will enable the use of 89Zr-DFO-girentuximab with PET/CT scans to detect clear cell renal cell carcinoma in patients with kidney masses. It aims to gather real-world safety and effectiveness data and understand how PET imaging affects patient management.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• 18 to 99 years old
• evidence of renal mass(es) obtained from conventional diagnostic imaging with CT or MRI
• agree to practice highly effective contraception until a minimum of 42 days after receiving study drug
Exclusion Criteria:
• mass known to be a metastasis of another primary tumor
• active non-renal cancer requiring therapy
• women who are pregnant or breastfeeding
Interventions:
Diagnostic Test: 89Zr-DFO-girentuximab
Conditions:
Cancer
Keywords:
Clear Cell Renal Cell Carcinoma, Kidney Cancer
Study Contact: Lucas Brown - brow4398@umn.edu
Principal Investigator: Ian Okazaki
IRB Number: STUDY00024231
See this study on ClinicalTrials.gov